Moderate

Secondary (functional) mitral regurgitation — chronic

Ischaemic/functional MR · Cardiac
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Secondary mitral regurgitation results from left-ventricular dilatation or regional dysfunction tethering a structurally normal valve, commonly after MI or in dilated cardiomyopathy. Guideline-directed heart failure therapy is the foundation, with transcatheter repair benefiting selected patients.

Red flags

  • Acute pulmonary oedema
  • Rapidly worsening symptoms despite optimal therapy
  • Haemodynamic instability (consider acute MR)
  • Progressive LV dilatation and falling EF
  • Severe pulmonary hypertension

Assessment

Differential diagnosis

  • Primary (degenerative) mitral regurgitation
  • Ischaemic functional MR
  • Atrial functional MR (from AF/LA dilatation)
  • Dilated cardiomyopathy-related MR
  • Acute MR (papillary rupture)
  • Mixed valve disease

Investigations

  • Transthoracic echo (EROA, regurgitant volume, LV size/function)
  • Transoesophageal echo for mechanism and intervention planning
  • Ischaemia/viability assessment where relevant
  • NT-proBNP
  • ECG and rhythm assessment
  • Right-heart catheterisation if pulmonary hypertension suspected

Management

  • Confirm MR is secondary and quantify severity
  • Establish the mechanism: ventricular (ischaemic/dilated) versus atrial
  • Optimise and maximise guideline-directed heart failure therapy first
  • Add cardiac resynchronisation therapy if indicated — it can reduce functional MR
  • Revascularise where viable ischaemic myocardium is contributing
  • Reassess MR severity after therapy optimisation (it often improves)
  • Refer persistent severe symptomatic secondary MR for heart-team evaluation
  • Offer transcatheter edge-to-edge repair to appropriately selected patients (per COAPT-type criteria)
  • Consider surgery when combined with other cardiac surgery
  • Manage atrial fibrillation and anticoagulate as indicated
  • Treat atrial functional MR by addressing AF and LA remodelling
  • Arrange heart-failure and valve-clinic follow-up

Drugs & doses

Sacubitril/valsartan 49/51 mg PO BD, titrate to 97/103 mg BD
Bisoprolol 1.25-10 mg PO OD titrated
Eplerenone 25-50 mg PO OD (or spironolactone)
Dapagliflozin 10 mg PO OD
Furosemide 40-120 mg PO OD for congestion

Disposition

Heart-failure and valve multidisciplinary team; transcatheter repair in selected patients after optimal medical therapy.

Complications & pitfalls

  • Progressive heart failure
  • Pulmonary hypertension
  • Atrial fibrillation
  • Recurrent hospitalisation
  • Procedural complications of valve intervention

Exam pearls

  • Guideline-directed medical therapy is the cornerstone — reassess MR after optimisation
  • Transcatheter edge-to-edge repair benefits a specific 'disproportionate MR' phenotype (COAPT)
  • CRT can reduce functional MR by improving LV geometry
  • The valve is structurally normal — the ventricle (or atrium) is the problem
  • Surgery alone for ventricular functional MR has not consistently improved survival

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.